Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants

被引:155
作者
Wentzensen, Nicolas [1 ]
Schiffman, Mark [1 ]
Dunn, Terence [2 ,3 ]
Zuna, Rosemary E. [2 ,3 ]
Gold, Michael A. [2 ,3 ,4 ]
Allen, Richard A. [2 ,3 ]
Zhang, Roy [2 ,3 ]
Sherman, Mark E. [1 ]
Wacholder, Sholom [1 ]
Walker, Joan [2 ,3 ]
Wang, Sophia S. [1 ]
机构
[1] Natl Canc Inst, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA
[2] Univ Oklahoma, Dept Obstet & Gynecol, Oklahoma City, OK USA
[3] Univ Oklahoma, Dept Pathol, Oklahoma City, OK USA
[4] Vanderbilt Univ, Dept Obstet & Gynecol, Nashville, TN USA
关键词
cervical cancer; HPV; SUCCEED; epidemiology; molecular; ATTRIBUTABLE RISK; HPV TYPES; WOMEN; LESIONS; PREVALENCE; NEOPLASIA; AGE; ACQUISITION; VACCINE; IMPACT;
D O I
10.1002/ijc.24528
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Determining the causal attribution of human papillomavirus (HPV) genotypes to cervical disease is important to estimate the effect of HPV vaccination and to establish a type spectrum for HPV-based screening. We analyzed the prevalence of HPV infections and their attribution to cervical disease in a population of 1,670 women referred to colposcopy for abnormal cytology at the University of Oklahoma. HPV genotyping was performed from cytology specimens using the Linear Array assay that detects 37 HPV genotypes. We used different methods of type attribution to revised cervical disease categories. We found very high prevalence of multiple HPV infections with up to 14 genotypes detected in single specimens. In all disease categories except for cancers, there was a significant trend of having more infections at a younger age. We did not see type interactions in multiple genotype infections. HPV16 was the most frequent genotype at all disease categories. Based on different attribution strategies, the attribution of vaccine genotypes (6, 11, 16, 18) ranged from 50.5 to 67.3% in cancers (n = 107), from 25.6 to 74.8% in CIN3 (n = 305), from 15.2 to 52.2% in CIN2 (n = 427), and from 6.6 to 26.0% in <CIN2 (n = 708). In the HSIL cytology group (n = 651), attribution ranged from 26.1 to 64.7%. The attribution of vaccine types to HSIL was substantially higher compared to the lower cytology categories. The potential range of HPV genotype attribution is wide at the disease categories <CIN2 to CIN3. Genotyping from cervical lesions and analyzing viral oncogene expression can improve estimates of HPV genotype attribution. (C) 2009 UICC
引用
收藏
页码:2151 / 2158
页数:8
相关论文
共 38 条
  • [1] ESTIMATING THE POPULATION ATTRIBUTABLE RISK FOR MULTIPLE RISK-FACTORS USING CASE-CONTROL DATA
    BRUZZI, P
    GREEN, SB
    BYAR, DP
    BRINTON, LA
    SCHAIRER, C
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 122 (05) : 904 - 913
  • [2] CIN2 is a much less reproducible and less valid diagnosis than CIN3: Results from a histological review of population-based cervical samples
    Carreon, Joseph D.
    Sherman, Mark E.
    Guillen, Diego
    Solomon, Diane
    Herrero, Rolando
    Jeronimo, Jose
    Wacholder, Sholom
    Rodriguez, Ana Cecilia
    Morales, Jorge
    Hutchinson, Martha
    Burk, Robert D.
    Schiffman, Mark
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2007, 26 (04) : 441 - 446
  • [3] A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica
    Castle, PE
    Schiffman, M
    Herrero, R
    Hildesheim, A
    Rodriguez, AC
    Bratti, MC
    Sherman, ME
    Wacholder, S
    Tarone, R
    Burk, RD
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (11) : 1808 - 1816
  • [4] Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections
    Chaturvedi, AK
    Myers, L
    Hammons, AF
    Clark, RA
    Dunlap, K
    Kissinger, PJ
    Hagensee, ME
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (10) : 2439 - 2445
  • [5] Carcinogenicity of human papillomaviruses
    Cogliano, V
    Baan, R
    Straif, K
    Grosse, Y
    Secretan, B
    El Ghissassi, F
    [J]. LANCET ONCOLOGY, 2005, 6 (04) : 204 - 204
  • [6] Classification of papillomaviruses
    de Villiers, EM
    Fauquet, C
    Broker, TR
    Bernard, HU
    zur Hausen, H
    [J]. VIROLOGY, 2004, 324 (01) : 17 - 27
  • [7] DNA extraction: An understudied and important aspect of HPV genotyping using PCR-based methods
    Dunn, S. Terence
    Allen, Richard A.
    Wang, Sophia
    Walker, Joan
    Schiffman, Mark
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2007, 143 (01) : 45 - 54
  • [8] Variations in the age-specific curves of human papillomavirus prevalence in women worldwide
    Franceschi, Silvia
    Herrero, Rolando
    Clifford, Gary M.
    Snijders, Peter J. F.
    Arslan, Annie
    Anh, Pham Thi Hoang
    Bosch, F. Xavier
    Ferreccio, Catterina
    Hieu, Nguyen Trong
    Lazcano-Ponce, Eduardo
    Matos, Elena
    Molano, Monica
    Qiao, You-Lin
    Rajkumar, Raj
    Ronco, Guglielmo
    de Sanjose, Silvia
    Shin, Hai-Rim
    Sukvirach, Sukhon
    Thomas, Jaiye O.
    Meijer, Chris J. L. M.
    Munoz, Nubia
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (11) : 2677 - 2684
  • [9] Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer
    Franco, EL
    Villa, LL
    Sobrinho, JP
    Prado, JM
    Rousseau, MC
    Désy, M
    Rohan, TE
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (05) : 1415 - 1423
  • [10] Gene polymorphisms in bladder cancer
    Franekova, Maria
    Halasova, Erika
    Bukovska, Eva
    Luptak, Jan
    Dobrota, Dusan
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2008, 26 (01) : 1 - 8